Atara Biotherapeutics, Inc.: Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel)
Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO is the
United States Pierre Fabre Posttransplant Lymphoproliferative Schwierige Zeiten Laure Sgandurra Pascal Touchon
Source: finanznachrichten.de